NCT03405337

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies

Evaluation of Patient and Physician Reported Reasons for Switching FVIII Replacement Therapies

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 160 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

This US study will assess hemophilia A patient characteristics, health history and reasons for switching or not switching from both patient/caregiver and physician perspectives. For this purpose, this research study will include hemophilia A: 1) patients who have switched from conventional therapy to new FVIII products with an improved PK profile. 2) patients who remain on conventional therapy (who have never switched) but have considered switching, including those patients who switched from conventional therapy to new FVIII products with improved pharmacokinetics and then subsequently "switched back" to conventional replacement therapy. In doing so, real world evidence will be obtained from both patient and physician perspectives offering key insights for effective therapeutic management of patients with hemophilia A and to more fully understand what drives patient switching from a patient perspective and a physician perspective.

Conditions

• Hemophilia A

Interventions

Type	Name	Description
DRUG	FVIII products	Adynovate, Eloctate, Afstyla, Kovaltry
DRUG	Conventional FVIII replacement therapies	Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha

Timeline

• Start date: 2018-02-14
• Primary completion: 2018-06-13
• Completion: 2018-06-13
• First posted: 2018-01-23
• Last updated: 2018-09-27

Locations

1 site across 1 country: United States